-
1.发明公开9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS 有权9-（芳基或杂芳基）-2-（吡唑基，吡咯烷基，或环戊基）氨基嘌呤衍生物作为抗癌剂
公开(公告)号：EP2964648A1
公开(公告)日：2016-01-13
申请号：EP14705029.8
申请日：2014-02-11
申请人： Merck Patent GmbH
发明人： HOELZEMANN, Guenter , DORSCH, Dieter , WEGENER, Ansgar , POESCHKE, Oliver , BUSCH, Michael , SEENISAMY, Jeyaprakashnarayanan
IPC分类号： C07D473/32 , A61K31/52 , A61P35/00
CPC分类号： C07D473/32 , A61K31/52 , Y02A50/409 , Y02A50/411
摘要： Compounds of the formula I in which X, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
-
公开(公告)号：EP2994471B1
公开(公告)日：2017-05-17
申请号：EP14716758.9
申请日：2014-04-09
申请人： Merck Patent GmbH
IPC分类号： C07D487/22 , C07D498/22 , A61K31/519 , A61P35/00
CPC分类号： A61K31/519 , C07D471/22 , C07D487/16 , C07D487/22 , C07D498/22
摘要： Compounds of the formula I in which X, Y, Q1, M, Q2 and B have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
摘要翻译： 其中X，Y，Q1，M，Q2和B具有权利要求1中所示含义的式I化合物是GCN2的抑制剂，尤其可用于治疗癌症。
-
公开(公告)号：EP2630129A1
公开(公告)日：2013-08-28
申请号：EP11761512.0
申请日：2011-09-22
申请人： Merck Patent GmbH
IPC分类号： C07D241/44 , C07D403/12 , C07D405/12 , C07D405/14 , C07D417/14 , A61K31/497 , A61P35/00
CPC分类号： C07D241/44 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/14 , C07D417/12 , C07D417/14
摘要： Compounds of the formula (I) in which R, R
1 and R
2 are each as defined in claim 1 are PI3K inhibitors and can be used inter alia for treatment of autoimmune disorders, inflammation, cardiovascular disorders, neurodegenerative disorders and tumours.-
4.发明公开TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER 有权三唑并[4,5-d]嘧啶衍生物对疾病如癌症的治疗
公开(公告)号：EP2964649A1
公开(公告)日：2016-01-13
申请号：EP14704286.5
申请日：2014-02-10
申请人： Merck Patent GmbH
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P37/00
CPC分类号： A61K31/519 , A61K31/5377 , C07D487/04 , C07D519/00 , Y02A50/409 , Y02A50/411
摘要： Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
-
公开(公告)号：EP2285788A1
公开(公告)日：2011-02-23
申请号：EP09757156.6
申请日：2009-05-08
申请人： Merck Patent GmbH
IPC分类号： C07D267/00 , A61K31/122 , A61K31/16 , A61K31/215 , A61K31/395 , C07C49/727 , C07C49/743 , A61P3/10
CPC分类号： C07D267/00 , C07C49/737 , C07C49/743 , C07C62/38 , C07C69/757 , C07C215/42 , C07C233/58 , C07C233/62 , C07C2603/26 , C07C2603/78
摘要： Novel terpenes and macrocycles are activators of TGR5 and can be used for the prevention and/or treatment of Diabetes Typ 2, obesity, neuropathy and/or nephropathy.
摘要翻译： 新型萜烯和大环化合物是TGR5的活化剂，可用于预防和/或治疗2型糖尿病，肥胖，神经病和/或肾病。
-
6.发明授权TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER 有权TRIAZOLO [4,5-D]嘧啶衍生物用于治疗诸如癌症的疾病
公开(公告)号：EP2964649B1
公开(公告)日：2017-05-10
申请号：EP14704286.5
申请日：2014-02-10
申请人： Merck Patent GmbH
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P37/00
CPC分类号： A61K31/519 , A61K31/5377 , C07D487/04 , C07D519/00 , Y02A50/409 , Y02A50/411
摘要： Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
摘要翻译： 其中R1和R2具有权利要求1中所示含义的式I化合物是GCN2的抑制剂，尤其可用于治疗癌症。
-
7.发明授权BENZYL PIPERIDINE COMPOUNDS AS LYSOPHOSPHATIDIC ACID (LPA) RECEPTOR ANTAGONIST 有权BENZYLPIPERIDINVERBINDUNGEN ALS溶血磷脂受体拮抗剂
公开(公告)号：EP2844648B1
公开(公告)日：2016-11-09
申请号：EP12758777.2
申请日：2012-09-07
申请人： Merck Patent GmbH
发明人： SCHIEMANN, Kai , STAEHLE, Wolfgang , BUSCH, Michael , WIENKE, Dirk , POESCHKE, Oliver , BURGER, Christa
IPC分类号： C07D401/04 , A61K31/4523 , A61P35/00 , A61P29/00 , C07D407/04 , C07D417/04
CPC分类号： C07D487/04 , A61K31/4525 , A61K31/4535 , A61K31/454 , A61K31/4545 , A61K31/4985 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/04 , C07D409/04 , C07D471/04
-
8.发明公开BENZYL PIPERIDINE COMPOUNDS AS LYSOPHOSPHATIDIC ACID (LPA) RECEPTOR ANTAGONIST 有权BENZYLPIPERIDINVERBINDUNGEN ALS溶血磷脂受体拮抗剂
公开(公告)号：EP2844648A1
公开(公告)日：2015-03-11
申请号：EP12758777.2
申请日：2012-09-07
申请人： Merck Patent GmbH
发明人： SCHIEMANN, Kai , STAEHLE, Wolfgang , BUSCH, Michael , WIENKE, Dirk , POESCHKE, Oliver , BURGER, Christa
IPC分类号： C07D401/04 , A61K31/4523 , A61P35/00 , A61P29/00 , C07D407/04 , C07D417/04
CPC分类号： C07D487/04 , A61K31/4525 , A61K31/4535 , A61K31/454 , A61K31/4545 , A61K31/4985 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/04 , C07D409/04 , C07D471/04
摘要： The invention provides novel substituted benzyl piperidine compounds according to Formula (I) as lysophosphatidic acid (LPA) receptor antagonists, their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.
-
9.发明授权9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS 有权9-（芳基或杂芳基）-2-（吡唑基，吡咯烷基或环戊基）氨基嘌呤衍生物作为抗癌剂
公开(公告)号：EP2964648B1
公开(公告)日：2016-11-16
申请号：EP14705029.8
申请日：2014-02-11
申请人： Merck Patent GmbH
发明人： HOELZEMANN, Guenter , DORSCH, Dieter , WEGENER, Ansgar , POESCHKE, Oliver , BUSCH, Michael , SEENISAMY, Jeyaprakashnarayanan
IPC分类号： C07D473/32 , A61K31/52 , A61P35/00
CPC分类号： C07D473/32 , A61K31/52 , Y02A50/409 , Y02A50/411
摘要： Compounds of the formula I in which X, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
-
公开(公告)号：EP2630129B1
公开(公告)日：2016-10-26
申请号：EP11761512.0
申请日：2011-09-22
申请人： Merck Patent GmbH
IPC分类号： C07D417/12 , C07D241/44 , C07D403/12 , C07D405/12 , C07D405/14 , C07D417/14 , C07D413/14 , C07D401/12 , C07D409/12
CPC分类号： C07D241/44 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/14 , C07D417/12 , C07D417/14
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.019 秒)
